Cargando…
Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures
Men with metastatic castration-resistant prostate cancer (mCRPC) carry poor prognosis despite the use of docetaxel-based regimens which has modest survival benefit shown by randomized clinical trials. Significant progress in the discovery of novel therapeutic agents has been made in the past few yea...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3425086/ https://www.ncbi.nlm.nih.gov/pubmed/22747660 http://dx.doi.org/10.1186/1756-8722-5-35 |